Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Terminal decisions take longer

A preliminary appraisal from the U.K.'s National Institute for Health and Clinical Excellence turning down coverage of Yondelis trabectedin from PharmaMar S.A. is one more sign that simply meeting the agency's new end of life criteria won't prevent companies from having to negotiate cost-sharing schemes to get covered by the National Health Service.

NICE noted in last month's preliminary appraisal that Yondelis meets the end of life criteria that aim to provide terminally ill patients access to treatments that NICE normally would deem too expensive to be covered by NHS.

The

Read the full 892 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE